SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR
SOPHiA GENETICS and AstraZeneca are expanding their collaboration to accelerate global liquid biopsy testing deployment. The partnership will extend MSK-ACCESS powered with SOPHiA DDM to 30 clinical institutions worldwide in 2025.
Key highlights:
- The liquid biopsy test detects genomic alterations from a single blood draw using advanced algorithms to analyze circulating tumor DNA
- This testing method offers advantages when traditional tissue biopsies are impractical due to cost, time, or invasiveness
- New data presented at AACR shows consistent accuracy across different laboratory settings
The expanded rollout supports AstraZeneca's real-world evidence initiatives and aims to validate decentralized liquid biopsy testing's clinical impact. The collaboration addresses a major industry challenge, as site-to-site result consistency has historically limited liquid biopsy adoption. Recent study results confirm the test maintains high analytical performance across multiple centers, matching the original standards set at Memorial Sloan Kettering Cancer Center.
SOPHiA GENETICS e AstraZeneca stanno ampliando la loro collaborazione per accelerare la diffusione globale dei test di biopsia liquida. La partnership porterà MSK-ACCESS potenziato con SOPHiA DDM in 30 istituzioni cliniche nel mondo entro il 2025.
Punti chiave:
- Il test di biopsia liquida rileva alterazioni genomiche da un singolo prelievo di sangue utilizzando algoritmi avanzati per analizzare il DNA tumorale circolante
- Questo metodo diagnostico offre vantaggi quando le biopsie tissutali tradizionali sono impraticabili per costi, tempi o invasività
- Nuovi dati presentati all'AACR dimostrano un'accuratezza costante in diversi laboratori
La diffusione ampliata supporta le iniziative di evidenza nel mondo reale di AstraZeneca e mira a convalidare l'impatto clinico dei test di biopsia liquida decentralizzati. La collaborazione affronta una sfida importante nel settore, poiché la coerenza dei risultati tra siti ha storicamente limitato l'adozione della biopsia liquida. I risultati recenti confermano che il test mantiene elevate prestazioni analitiche in più centri, rispettando gli standard originali del Memorial Sloan Kettering Cancer Center.
SOPHiA GENETICS y AstraZeneca están ampliando su colaboración para acelerar la implementación global de pruebas de biopsia líquida. La alianza extenderá MSK-ACCESS potenciado con SOPHiA DDM a 30 instituciones clínicas en todo el mundo para 2025.
Puntos clave:
- La prueba de biopsia líquida detecta alteraciones genómicas a partir de una sola extracción de sangre utilizando algoritmos avanzados para analizar el ADN tumoral circulante
- Este método ofrece ventajas cuando las biopsias tradicionales de tejido son imprácticas debido a costos, tiempo o invasividad
- Nuevos datos presentados en AACR muestran una precisión consistente en diferentes laboratorios
La expansión apoya las iniciativas de evidencia en el mundo real de AstraZeneca y busca validar el impacto clínico de las pruebas de biopsia líquida descentralizadas. La colaboración aborda un desafío importante en la industria, ya que la consistencia de resultados entre sitios ha limitado históricamente la adopción de biopsias líquidas. Los resultados recientes confirman que la prueba mantiene un alto rendimiento analítico en múltiples centros, igualando los estándares originales establecidos en el Memorial Sloan Kettering Cancer Center.
SOPHiA GENETICS와 AstraZeneca가 전 세계 액체 생검 검사 도입 가속화를 위해 협력을 확대하고 있습니다. 이 파트너십은 2025년까지 MSK-ACCESS와 SOPHiA DDM 기반 검사를 전 세계 30개 임상 기관으로 확장할 예정입니다.
주요 내용:
- 액체 생검 검사는 단일 혈액 채취로 순환 종양 DNA를 분석하는 고급 알고리즘을 사용하여 유전체 변이를 감지합니다
- 이 검사 방법은 비용, 시간 또는 침습성으로 인해 전통적인 조직 생검이 어려운 경우에 유리합니다
- AACR에서 발표된 새로운 데이터는 다양한 실험실 환경에서 일관된 정확성을 보여줍니다
확대된 도입은 AstraZeneca의 실제 근거 기반 이니셔티브를 지원하며, 분산형 액체 생검 검사의 임상적 영향을 검증하는 것을 목표로 합니다. 이 협력은 현장 간 결과 일관성 부족으로 인해 액체 생검 도입이 제한되었던 주요 산업 과제를 해결합니다. 최근 연구 결과는 이 검사가 여러 센터에서 높은 분석 성능을 유지하며 Memorial Sloan Kettering Cancer Center에서 설정한 원래 기준과 일치함을 확인했습니다.
SOPHiA GENETICS et AstraZeneca étendent leur collaboration pour accélérer le déploiement mondial des tests de biopsie liquide. Ce partenariat étendra MSK-ACCESS propulsé par SOPHiA DDM à 30 institutions cliniques dans le monde en 2025.
Points clés :
- Le test de biopsie liquide détecte les altérations génomiques à partir d'un seul prélèvement sanguin en utilisant des algorithmes avancés pour analyser l'ADN tumoral circulant
- Cette méthode de test offre des avantages lorsque les biopsies tissulaires traditionnelles sont impraticables en raison des coûts, du temps ou de l'invasivité
- De nouvelles données présentées à l'AACR montrent une précision constante dans différents laboratoires
Le déploiement élargi soutient les initiatives d'AstraZeneca en matière de preuves issues du monde réel et vise à valider l'impact clinique des tests de biopsie liquide décentralisés. La collaboration répond à un défi majeur de l'industrie, car la cohérence des résultats d'un site à l'autre a historiquement limité l'adoption de la biopsie liquide. Les résultats récents confirment que le test maintient une haute performance analytique dans plusieurs centres, conformément aux normes originales établies au Memorial Sloan Kettering Cancer Center.
SOPHiA GENETICS und AstraZeneca erweitern ihre Zusammenarbeit, um die weltweite Einführung von Liquid-Biopsy-Tests zu beschleunigen. Die Partnerschaft wird MSK-ACCESS mit SOPHiA DDM bis 2025 auf 30 klinische Einrichtungen weltweit ausweiten.
Wichtige Punkte:
- Der Liquid-Biopsy-Test erkennt genomische Veränderungen aus einer einzigen Blutprobe mithilfe fortschrittlicher Algorithmen zur Analyse zirkulierender Tumor-DNA
- Diese Testmethode bietet Vorteile, wenn herkömmliche Gewebebiopsien aufgrund von Kosten, Zeit oder Invasivität unpraktisch sind
- Neue auf der AACR vorgestellte Daten zeigen eine konsistente Genauigkeit in verschiedenen Laboreinstellungen
Die erweiterte Einführung unterstützt AstraZenecas Initiativen zu Real-World-Evidenz und zielt darauf ab, die klinische Wirkung dezentralisierter Liquid-Biopsy-Tests zu validieren. Die Zusammenarbeit adressiert eine große Herausforderung der Branche, da die Konsistenz der Ergebnisse zwischen Standorten die Akzeptanz von Liquid Biopsies historisch begrenzt hat. Aktuelle Studienergebnisse bestätigen, dass der Test in mehreren Zentren eine hohe analytische Leistung aufrechterhält und die ursprünglichen Standards des Memorial Sloan Kettering Cancer Center erfüllt.
- Expanded collaboration with major pharmaceutical company AstraZeneca to accelerate global deployment of liquid biopsy testing
- Significant scaling of deployment to 30 clinical institutions worldwide in 2025
- Real-world data demonstrates high analytical performance and consistency of MSK-ACCESS powered with SOPHiA DDM across multiple laboratory settings
- Technology enables cost-effective and less invasive cancer monitoring compared to traditional tissue biopsies
- None.
Insights
SOPHiA GENETICS expands AstraZeneca collaboration to scale liquid biopsy technology globally, strengthening commercial position in precision oncology diagnostics.
The expanded collaboration between SOPHiA GENETICS and AstraZeneca marks a strategic advancement in SOPHiA's commercialization strategy for their liquid biopsy technology. The planned extension to 30 clinical institutions worldwide in 2025 indicates meaningful scaling of their deployment infrastructure, though investors should note this is a forward-looking initiative rather than an immediate market expansion.
What's particularly valuable from a commercial perspective is the technical validation presented at AACR. The press release highlights that site-to-site discordance has been a major adoption barrier for liquid biopsy technologies. The interim study results demonstrating consistent analytical performance across multiple laboratory settings address this specific obstacle, potentially removing a key hurdle to broader market acceptance and adoption.
For SOPHiA GENETICS, this expanded collaboration with a major pharmaceutical company provides institutional validation of their technology approach. The decentralized testing model they've developed with Memorial Sloan Kettering differs from centralized laboratory models by enabling testing at the point of care, which can offer workflow and turnaround time advantages for healthcare providers.
The contribution to AstraZeneca's real-world evidence initiatives suggests the partnership has strategic value beyond just technology deployment. However, the press release doesn't disclose financial terms or revenue projections, making it difficult to quantify the direct economic impact of this expanded collaboration on SOPHiA's future revenue streams.
SOPHiA's liquid biopsy expansion solves critical lab-to-lab consistency problems, enabling wider access to advanced cancer diagnostics globally.
The expanded deployment of MSK-ACCESS® powered with SOPHiA DDM™ addresses one of liquid biopsy's most persistent technical challenges: analytical consistency across different testing environments. The technology analyzes circulating tumor DNA from blood samples, providing a critical diagnostic option when traditional tissue biopsies are impractical due to cost, turnaround time, insufficient tissue, or procedural invasiveness.
The data presented at AACR demonstrating robust transferability is technically significant. Historically, molecular diagnostic tests developed at specialized cancer centers like Memorial Sloan Kettering have been difficult to reproduce with the same sensitivity and specificity at community hospitals or regional laboratories. This "transferability problem" has limited the adoption of advanced molecular diagnostics, particularly for complex applications like liquid biopsy.
The multi-center study results showing high analytical performance consistent with the original Memorial Sloan Kettering test indicates SOPHiA has overcome a major technical barrier. By maintaining analytical consistency across diverse laboratory settings, this decentralized approach helps bridge the precision oncology gap between leading academic centers and community practice settings.
While the press release notes the technology can "complement solid tissue testing," it appropriately acknowledges that liquid biopsy isn't a universal replacement for traditional biopsies. The implementation across 30 global clinical institutions will generate valuable insights into optimal clinical workflows and use cases for this technology in diverse healthcare systems.
Developed in collaboration with Memorial Sloan Kettering Cancer Center, MSK-ACCESS® powered with SOPHiA DDM™ is an innovative liquid biopsy testing application designed to detect actionable genomic alterations from a single blood draw using proprietary, state-of-the-art algorithms which analyze circulating tumor DNA (ctDNA). The application supports real-time cancer monitoring and treatment selection when traditional tissue biopsies are not feasible due to cost, turnaround time, insufficient tissue, or the invasiveness of the procedure.
The expanded rollout will continue to contribute to AstraZeneca's global real-world evidence initiatives and help further validate the clinical impact of decentralized liquid biopsy testing across diverse healthcare systems. By increasing the availability of MSK-ACCESS® powered with SOPHiA DDM™, SOPHiA GENETICS and AstraZeneca aim to understand further how liquid biopsy testing can complement solid tissue testing and, in some cases, provide greater benefit for labs and patients.
The announcement coincides with SOPHiA GENETICS's presentation at AACR, in which the company presented data demonstrating the robust transferability of the decentralized MSK-ACCESS® powered with SOPHiA DDMTM solution. Historically, site-to-site discordance has been a major barrier to the widespread adoption of liquid biopsy testing. SOPHiA GENETICS presented real-world data highlighting the consistent accuracy and precision of MSK-ACCESS® powered with SOPHiA DDMTM across various laboratory settings. Interim results from the multi-center study demonstrated the high analytical performance of the decentralized test in line with the original single-site test at Memorial Sloan Kettering Cancer Center in
"Our collaboration with AstraZeneca represents a significant step toward scaling next-generation oncology diagnostics globally," said Ross Muken, President, SOPHiA GENETICS. "This expanded deployment reflects the growing momentum behind liquid biopsy and our shared ambition to make these technologies more accessible and impactful worldwide."
Visit SOPHiA GENETICS at the American Association for Cancer Research's Annual Meeting in
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the
Media Contact:
wpp_sophiagenetics@gcihealth.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-expanded-collaboration-with-astrazeneca-to-accelerate-liquid-biopsy-testing-globally-from-aacr-302439912.html
SOURCE SOPHiA GENETICS
FAQ
What is the new AstraZeneca and SOPHiA GENETICS (SOPH) collaboration expansion announced at AACR 2025?
How does the MSK-ACCESS liquid biopsy test by SOPHiA GENETICS (SOPH) work?
What results did SOPHiA GENETICS (SOPH) present at AACR 2025 for their liquid biopsy test?
Where can investors learn more about SOPHiA GENETICS (SOPH) AstraZeneca collaboration?
What are the benefits of SOPHiA GENETICS (SOPH) liquid biopsy testing expansion?
